Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription


9 Clin Infect Dis
1 Infect Immun
2 J Immunol
3 J Infect
1 J Pediatr
1 J Virol
4 Lancet
1 MMWR Morb Mortal Wkly Rep
1 Pediatrics
1 PLoS Biol
1 PLoS Comput Biol
1 PLoS Med
8 PLoS One
1 Proc Natl Acad Sci U S A
18 Vaccine

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles


  1. WISE J
    Covid-19: Vaccine effectiveness wanes more rapidly for cancer patients, study finds.
    BMJ. 2022;377:o1305.

  2. GAZIT S, Saciuk Y, Perez G, Peretz A, et al
    Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study.
    BMJ. 2022;377:e071113.
    PubMed         Abstract available

  3. HORDIJK L, Patnaik P
    Covid-19-How Europe's vaccine donations went tragically wrong.
    BMJ. 2022;377:o1286.

    Clin Infect Dis

  4. ROTTENSTREICH A, Vorontsov O, Alfi O, Zarbiv G, et al
    Maternal and Neonatal SARS-CoV-2 Omicron Variant Neutralization after Antenatal mRNA Vaccination.
    Clin Infect Dis. 2022 May 24. pii: 6590984. doi: 10.1093.
    PubMed         Abstract available

  5. SHAPIRO JR, Sitaras I, Park HS, Aytenfisu TY, et al
    Association of frailty, age, and biological sex with SARS-CoV-2 mRNA vaccine-induced immunity in older adults.
    Clin Infect Dis. 2022 May 24. pii: 6590987. doi: 10.1093.
    PubMed         Abstract available

  6. LAGOUSI T, Papadatou I, Strempas P, Chatzikalil E, et al
    Clin Infect Dis. 2022 May 24. pii: 6590985. doi: 10.1093.
    PubMed         Abstract available

  7. EYAL N, Gheaus A, Gosseries A, Magalhaes M, et al
    COVID vaccine prioritization in low- and middle-income countries may justifiably depart from high-income countries' age priorities.
    Clin Infect Dis. 2022 May 24. pii: 6590988. doi: 10.1093.
    PubMed         Abstract available

  8. LOFGREN E, Naumova EN, Gorski J, Naumov Y, et al
    How drivers of seasonality in respiratory infections may impact vaccine strategy: a case study in how COVID-19 may help us solve one of influenza's biggest challenges.
    Clin Infect Dis. 2022 May 24. pii: 6590989. doi: 10.1093.
    PubMed         Abstract available

  9. CORRADINI P, Agrati C, Apolone G, Mantovani A, et al
    Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study.
    Clin Infect Dis. 2022 May 24. pii: 6590993. doi: 10.1093.
    PubMed         Abstract available

  10. EPSI NJ, Richard SA, Lindholm DA, Mende K, et al
    Understanding 'hybrid immunity': comparison and predictors of humoral immune responses to SARS-CoV-2 infection and COVID-19 vaccines.
    Clin Infect Dis. 2022 May 24. pii: 6591282. doi: 10.1093.
    PubMed         Abstract available

  11. GRIMA AA, Murison KR, Simmons AE, Tuite AR, et al
    Relative Virulence of SARS-CoV-2 Among Vaccinated and Unvaccinated Individuals Hospitalized with SARS-CoV-2.
    Clin Infect Dis. 2022 May 25. pii: 6591845. doi: 10.1093.
    PubMed         Abstract available

  12. PETROS BA, Turcinovic J, Welch NL, White LF, et al
    Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations.
    Clin Infect Dis. 2022 May 25. pii: 6591846. doi: 10.1093.
    PubMed         Abstract available

    Infect Immun

  13. KAUR R, Pichichero M
    Lipidation of Haemophilus influenzae Antigens P6 and OMP26 Improves Immunogenicity and Protection against Nasopharyngeal Colonization and Ear Infection.
    Infect Immun. 2022;90:e0067821.
    PubMed         Abstract available

    J Immunol

  14. RICHERT L, Lelievre JD, Lacabaratz C, Hardel L, et al
    T Cell Immunogenicity, Gene Expression Profile, and Safety of Four Heterologous Prime-Boost Combinations of HIV Vaccine Candidates in Healthy Volunteers: Results of the Randomized Multi-Arm Phase I/II ANRS VRI01 Trial.
    J Immunol. 2022 May 25. pii: jimmunol.2101076. doi: 10.4049/jimmunol.2101076.
    PubMed         Abstract available

  15. KRMESKA V, Aggio JB, Nylen S, Wowk PF, et al
    Cyclooxygenase-Derived Prostaglandin E2 Drives IL-1-Independent Mycobacterium bovis Bacille Calmette-Guerin-Triggered Skin Dendritic Cell Migration to Draining Lymph Node.
    J Immunol. 2022;208:2549-2557.
    PubMed         Abstract available

    J Infect

  16. NISHIKIMI A, Watanabe K, Watanabe A, Yasuoka M, et al
    Immune responses to COVID-19 vaccine BNT162b2 in workers at a research institute in Japan: 6-month follow-up survey.
    J Infect. 2022 May 20. pii: S0163-4453(22)00307.

  17. CHEN CH, Janapatla RP, Su LH, Li HC, et al
    Incidence rates, emerging serotypes and genotypes, and antimicrobial susceptibility of pneumococcal disease in Taiwan: A multi-center clinical microbiological study after PCV13 implementation.
    J Infect. 2022;84:788-794.
    PubMed         Abstract available

  18. PAPAILIOU S, Soldatou A, Marmarinos A, Avgeris M, et al
    Inadequate protection against measles and rubella among pregnant women in Greece during the last measles outbreak.
    J Infect. 2022;84:e95-e97.

    J Pediatr

  19. HOSTE L, Soriano-Arandes A, Buddingh EP, Whittaker E, et al
    SARS-CoV-2 vaccination in children with a history of MIS-C: an international survey.
    J Pediatr. 2022 May 19. pii: S0022-3476(22)00438.
    PubMed         Abstract available

    J Virol

  20. DELVA JL, Van Waesberghe C, Van Den Broeck W, Lamote JA, et al
    The Attenuated Pseudorabies Virus Vaccine Strain Bartha Hyperactivates Plasmacytoid Dendritic Cells by Generating Large Amounts of Cell-Free Virus in Infected Epithelial Cells.
    J Virol. 2022 May 23:e0219921. doi: 10.1128/jvi.02199.
    PubMed         Abstract available


  21. KUEHN BM
    Cardiac Complications More Common After COVID-19 Than Vaccination.
    JAMA. 2022;327:1951.

  22. OSTER ME, Shay DK, Shimabukuro TT
    Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US-Reply.
    JAMA. 2022;327:2020-2021.

  23. WEISS SR
    Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US.
    JAMA. 2022;327:2019-2020.


  24. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.

  25. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.

  26. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.

    Eliminating cholera in Haiti.
    Lancet. 2022;399:1928-1929.

    MMWR Morb Mortal Wkly Rep

  28. WHITEHILL F, Bonaparte S, Hartloge C, Greenberg L, et al
    Rabies in a Dog Imported from Azerbaijan - Pennsylvania, 2021.
    MMWR Morb Mortal Wkly Rep. 2022;71:686-689.
    PubMed         Abstract available


  29. KARATZIOS C, Scuccimarri R, Chedeville G, Basfar W, et al
    Multisystem Inflammatory Syndrome Following SARS-CoV-2 Vaccination in Two Children.
    Pediatrics. 2022 May 26. pii: 188099. doi: 10.1542/peds.2021-055956.
    PubMed         Abstract available

    PLoS Biol

  30. LU-CULLIGAN A, Tabachnikova A, Perez-Then E, Tokuyama M, et al
    No evidence of fetal defects or anti-syncytin-1 antibody induction following COVID-19 mRNA vaccination.
    PLoS Biol. 2022;20:e3001506.
    PubMed         Abstract available

    PLoS Comput Biol

  31. GOZZI N, Chinazzi M, Davis JT, Mu K, et al
    Anatomy of the first six months of COVID-19 vaccination campaign in Italy.
    PLoS Comput Biol. 2022;18:e1010146.
    PubMed         Abstract available

    PLoS Med

  32. JIN P, Guo X, Chen W, Ma S, et al
    Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    PLoS Med. 2022;19:e1003953.
    PubMed         Abstract available

    PLoS One

  33. AGHAMIR SMK, Khatami F, Farrokhpour H, Oliveira Reis L, et al
    Oncologic outcomes of Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer: A meta-analysis.
    PLoS One. 2022;17:e0267934.
    PubMed         Abstract available

  34. NISHIMURA M, Sugawa S, Ota S, Suematsu E, et al
    Detection of silent infection of severe acute respiratory syndrome coronavirus 2 by serological tests.
    PLoS One. 2022;17:e0267566.
    PubMed         Abstract available

  35. NG JWJ, Vaithilingam S, Nair M, Hwang LA, et al
    Key predictors of COVID-19 vaccine hesitancy in Malaysia: An integrated framework.
    PLoS One. 2022;17:e0268926.
    PubMed         Abstract available

  36. RAQIB R, Sarker P, Akhtar E, Nurul Huda TM, et al
    Seroprevalence of SARS-CoV-2 infection and associated factors among Bangladeshi slum and non-slum dwellers in pre-COVID-19 vaccination era: October 2020 to February 2021.
    PLoS One. 2022;17:e0268093.
    PubMed         Abstract available

  37. SILVA EKVB, Bomfim CG, Barbosa AP, Noda P, et al
    Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in rats.
    PLoS One. 2022;17:e0268434.
    PubMed         Abstract available

  38. SPRENGHOLZ P, Henkel L, Betsch C
    Payments and freedoms: Effects of monetary and legal incentives on COVID-19 vaccination intentions in Germany.
    PLoS One. 2022;17:e0268911.
    PubMed         Abstract available

  39. AHETO JMK, Pannell O, Dotse-Gborgbortsi W, Trimner MK, et al
    Multilevel analysis of predictors of multiple indicators of childhood vaccination in Nigeria.
    PLoS One. 2022;17:e0269066.
    PubMed         Abstract available

  40. ASRI A, Asri V, Renerte B, Follmi-Heusi F, et al
    Which hospital workers do (not) want the jab? Behavioral correlates of COVID-19 vaccine willingness among employees of Swiss hospitals.
    PLoS One. 2022;17:e0268775.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  41. ZHU X, Han J, Sun W, Puente-Massaguer E, et al
    Influenza chimeric hemagglutinin structures in complex with broadly protective antibodies to the stem and trimer interface.
    Proc Natl Acad Sci U S A. 2022;119:e2200821119.
    PubMed         Abstract available


  42. CHANG CM, Awanye AM, Marsay L, Dold C, et al
    Application of a Neisseria meningitidis antigen microarray to identify candidate vaccine proteins from a human Phase I clinical trial.
    Vaccine. 2022 May 21. pii: S0264-410X(22)00616.
    PubMed         Abstract available

  43. SIQUEIRA PG, Duarte HO, Moura MDC
    Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00633.
    PubMed         Abstract available

  44. CARSON B, Isaacs J, Carilli T
    Jabbing together? The complementarity between social capital, formal public health rules, and COVID-19 vaccine rates in the United States.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00612.
    PubMed         Abstract available

  45. MOLLER A, Schwamborn K, Spillmann A, Hoogstraate J, et al
    Travel vaccines are strongly associated to reduced mortality in prostate cancer patients - a real effect or residual confounding?
    Vaccine. 2022 May 21. pii: S0264-410X(22)00611.
    PubMed         Abstract available

  46. ROBERTSON DA, Mohr KS, Barjakova M, Lunn PD, et al
    Experimental pre-tests of public health communications on the COVID-19 vaccine: A null finding for medical endorsement, risk and altruism.
    Vaccine. 2022 May 16. pii: S0264-410X(22)00613.
    PubMed         Abstract available

  47. LLAVE CL, Uy MEV, Lam HY, Aldaba JG, et al
    The cost-effectiveness of human papillomavirus vaccination in the Philippines.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00609.
    PubMed         Abstract available

  48. FOO D, Sarna M, Pereira G, Moore HC, et al
    Maternal influenza vaccination and child mortality: Longitudinal, population-based linked cohort study.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00614.
    PubMed         Abstract available

  49. IWATA S, Sonoyama T, Kamitani A, Shibata R, et al
    Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00494.
    PubMed         Abstract available

  50. KITCHEN M, Leierer G, Kistner O, Wodal W, et al
    High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00575.
    PubMed         Abstract available

  51. MCELFISH PA, Selig JP, Scott AJ, Rowland B, et al
    Associations between 5-year influenza vaccination and sociodemographic factors and healthcare access among Arkansans.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00615.
    PubMed         Abstract available

  52. STEELFISHER GK, Caporello H, McIntosh R, Muhammad Safdar R, et al
    Preventing erosion of oral polio vaccine acceptance: A role for vaccinator visits and social norms.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00567.
    PubMed         Abstract available

  53. ZHANG Y, Lin L, Yang J, Lv Q, et al
    Two Bordetella bronchiseptica attenuated vaccine candidates confer protection against lethal challenge with B. Bronchiseptica and Pasteurella multocida toxin in mouse models.
    Vaccine. 2022 May 19. pii: S0264-410X(22)00604.
    PubMed         Abstract available

  54. AHMED S, Iqbal J, Sadiq K, Umrani F, et al
    Association of Anti-Rotavirus IgA Seroconversion with Growth, Environmental Enteric Dysfunction and Enteropathogens in Rural Pakistani Infants.
    Vaccine. 2022;40:3444-3451.
    PubMed         Abstract available

  55. SALO-TUOMINEN K, Teros-Jaakkola T, Toivonen L, Ollila H, et al
    Parental socioeconomic and psychological determinants of the 2009 pandemic influenza A(H1N1) vaccine uptake in children.
    Vaccine. 2022 May 17. pii: S0264-410X(22)00582.
    PubMed         Abstract available

  56. VESIKARI T, Saez-Llorens X, Blazevic V, Lopez P, et al
    Immunogenicity of a bivalent virus-like particle norovirus vaccine in children from 1 to 8 years of age: A phase 2 randomized, double-blind study.
    Vaccine. 2022 May 17. pii: S0264-410X(22)00550.
    PubMed         Abstract available

  57. FEIKIN DR, Abu-Raddad LJ, Andrews N, Davies MA, et al
    Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00523.
    PubMed         Abstract available

  58. ALYA WA, Maraqa B, Nazzal Z, Odeh M, et al
    COVID-19 vaccine uptake and its associated factors among Palestinian healthcare workers: Expectations beaten by reality.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00610.
    PubMed         Abstract available

  59. POSTMA M, Biundo E, Chicoye A, Devlin N, et al
    Capturing the value of vaccination within health technology assessment and health economics: Country analysis and priority value concepts.
    Vaccine. 2022 May 18. pii: S0264-410X(22)00442.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.